By Nancy Lapid (Reuters) -Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the ...

The findings add to other research showing a lower risk of obesity-related cancers in patients taking GLP-1 drugs, a class of ...

After questions and criticism online, Janelle Rohner says she should have disclosed her decision to take a GLP-1.

GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes compared with dipeptidyl ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to ...

Dr. Rubinstein has years of experience working with patients to help them achieve their desired goals in a realistic, ...

David Kessler has lost more than 60 pounds on weight-loss drugs and believes they can change the trajectory of chronic ...

VinFuture Prize holds the distinction of being the first major international science and technology award to recognize and ...

If you're one of the millions of Americans who have used or thought about using GLP-1 weight-loss drugs, it’s important to ...

Despite the popularity of semaglutide drugs like Ozempic and Wegovy for weight loss, surveys suggest that most people still ...

New review confirms psychiatric safety of commonly used glucagon-like peptide 1 receptor agonists among patients without ...